RCKTNasdaqPharmaceutical PreparationsFiscal year ends December 31

ROCKET PHARMACEUTICALS, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026

$2.24+0.06 (+2.75%)

Close on Oct 19, 2026

Market cap: $256.51M
P/E (TTM): –
Dividend yield: –

ROCKET PHARMACEUTICALS, INC. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31
Cash & Equivalents	78	165	57	142	234	299	187	113	18	9.67	15	3.62	13
Short-Term Investments	111	209	317	216	156	186	119	94	0	97	31	–	–
Cash & Short-Term Investments	189	372	408	358	389	483	304	213	100	126	111	3.62	13
Prepaid Expenses & Other	3.81	5.85	5.05	7.67	3.32	4.63	3.64	3.36	0.81	1.88	1.09	0.05	–
Total Current Assets	193	378	378	364	392	487	308	209	19	128	112	3.67	–
Property, Plant & Equipment	28	37	39	29	22	19	30	2.03	0.99	1.13	0.81	–	–
Gross Property, Plant & Equipment	57	58	53	38	28	21	30	2.51	1.26	1.56	1.07	0.22	–
Accumulated Depreciation	-29	-21	-14	-9.09	-5.22	-2.05	-0.91	-0.48	-0.27	-0.43	-0.26	-0.22	–
Long-Term Investments	–	0	34	43	0	–	0	7.40	0	–	–	–	–
Operating Lease Right-of-Use Assets	3.21	4.17	3.90	1.97	1.57	0.91	2.05	0	–	–	–	–	–
Goodwill	39	39	39	39	31	31	31	31	0	–	–	–	–
Intangible Assets	25	25	25	26	0	–	–	–	–	–	–	–	–
Other Long-Term Assets	–	–	–	–	–	–	–	–	0.17	0.17	0.14	1.85	–
Total Assets	330	528	566	552	497	591	372	251	20	130	113	5.52	–
Accounts Payable	27	38	46	37	20	25	17	15	4.52	1.59	1.63	1.15	–
Accrued Expenses	–	–	–	–	–	–	–	–	2.37	4.25	2.51	0.99	–
Current Portion of Leases	1.00	1.00	0.93	0.77	0.86	0.63	0.96	0	–	–	–	–	–
Current Income Taxes Payable	0	–	–	–	–	–	–	–	–	–	–	–	–
Total Current Liabilities	30	41	49	39	22	33	18	15	4.52	7.04	4.14	7.22	–
Long-Term Debt	–	–	–	–	–	–	–	–	–	–	–	2.55	–
Long-Term Leases	2.60	3.26	2.97	1.09	0.91	0.50	1.44	0	–	–	–	–	–
Operating Lease Liabilities	3.60	4.26	3.90	1.86	1.77	1.12	2.40	0	–	–	–	–	–
Other Long-Term Liabilities	1.06	1.14	2.94	2.60	0.08	0.14	0.02	0.46	0.40	0.48	0.37	0.02	–
Total Liabilities	53	64	74	62	42	87	65	57	4.63	56	4.51	10	–
Total Debt	–	–	–	–	–	–	–	–	–	–	–	2.55	–
Common Stock	1.08	1.07	0.90	0.79	0.65	0.61	0.55	0.45	0.07	0.07	0.26	0.01	–
Additional Paid-In Capital	1,717	1,680	1,451	1,203	946	826	490	300	5.34	312	305	76	–
Retained Earnings	-1,441	-1,218	-959	-714	-492	-323	-183	-106	-31	-239	-196	-128	–
Treasury Stock	–	–	0	-0.05	0	0	-0.05	-0.67	0	–	–	–	–
Comprehensive Income & Other	-0.03	0.07	0.32	-0.36	-0.16	-0.04	0.02	-0.13	0	-0.05	-0.01	–	–
Shareholders' Equity	277	463	493	490	455	504	307	194	16	8.37	16	-52	-39
Total Equity	277	463	493	490	455	504	307	194	16	8.37	16	-52	-39
Total Liabilities & Equity	330	528	566	552	497	591	372	251	20	130	113	5.52	–
Shares Outstanding(shares)	108	106	90	79	65	61	55	45	6.80	6.75	6.61	0.26	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -60.3%

Financial strength

Current ratio: 9.24
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 716.8%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 0.70
Dividend yield: –